3 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
Follow T-Vec: new trials by email Literature Review of T-Vec trials Research Report on T-Vec
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Panitumumab, Talimogene Laherparepvec - Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma | Phase 1 | Terminated | Rutgers, The State University of New Jersey | 5 | 2020-01-31 | 2026-01-23 |
| Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted Ipilimumab, Nivolumab, Talimogene Laherparepvec - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 6 | 2019-07-10 | 2023-08-15 |
| Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer Capecitabine, Fluorouracil, Leucovorin - Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 3 | 2019-05-14 | 2024-05-23 |
Breast Carcinoma In Situ (1) · Rectal Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1) · Rutgers, The State University of New Jersey (1)
United States (3)
Adam C Berger, MD, FACS (1) · John A Glaspy (1) · Nageshwara V Dasari (1)
P30CA072720 (1), UM1CA186688 (1)